Skip to main content
Clinical Trials/NCT05330117
NCT05330117
Completed
Not Applicable

Transcutaneous Electrical Nerve Stimulation Analgesia During Outpatient Operative Cystoscopy for Overactive Bladder: A Randomized Control Trial (TENSOB Study)

University of Rochester1 site in 1 country100 target enrollmentDecember 14, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Urinary Incontinence
Sponsor
University of Rochester
Enrollment
100
Locations
1
Primary Endpoint
Mean pain measured by Visual Analog Scale (VAS)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This will be a double blind randomized control trial in men and women with urinary urge incontinence that are undergoing outpatient operative cystoscopy for Onabotulinumtoxin A chemo denervation as third line therapy for overactive bladder (OAB) or urinary urge incontinence (UUI). Subjects will be identified by the University of Rochester Urologists and Urogynecologists participating in the study who currently oversee urinary urge incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia and the second group will have cystoscopy with placebo TENS.

Registry
clinicaltrials.gov
Start Date
December 14, 2020
End Date
March 3, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Paula Doyle

Professor

University of Rochester

Eligibility Criteria

Inclusion Criteria

  • Men and Women, Age ≥18 years
  • Diagnosis of OAB/UUI,
  • Scheduled to undergo intravesical Botox injections in the office
  • Able to read/write English
  • Exclusion criteria:
  • Currently undergoing Sacral Neuromodulation
  • Cutaneous damage such as ulcers or broken skin on target treatment area
  • Currently implanted cardiac pacemaker or defibrillator
  • Pre-procedural use of opioids for pain management, less than 8 hours from last dose
  • Participants with altered sensation below the umbilicus

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Mean pain measured by Visual Analog Scale (VAS)

Time Frame: within 10 minutes after procedure

The VAS for pain consists of a 100-mm-long horizontal line where 0-mm equals no pain and 100-mm equals worst possible pain.

Secondary Outcomes

  • Mean pain measured by Likert scale(within 10 minutes after procedure)
  • Number of participants with side effects(within 10 minutes after procedure)
  • Mean satisfaction with the procedure(within 10 minutes after procedure)
  • Number of participants who guessed correctly whether they were given the active TENS or placebo TENS(within 10 minutes after procedure)

Study Sites (1)

Loading locations...

Similar Trials